Ghosh Subhadeep, Shankar Subramanian, Chatterjee Kaustuv, Chatterjee Kaushik, Yadav Arun Kumar, Pandya Kapil, Suryam Vani, Agrawal Sunil, Ray Sougat, Phutane Vivek, Datta Rajat
Col AFMS (Health), O/o DGAFMS, New Delhi, India.
Consultant (Medicine & Clinical Immunology), Air Cmde AFMS (P&T), O/o DGAFMS, New Delhi, India.
Med J Armed Forces India. 2021 Jul;77(Suppl 2):S264-S270. doi: 10.1016/j.mjafi.2021.06.032. Epub 2021 Jul 26.
On 16 Jan 2021, India launched its immunization program against COVID-19. Among the first recipients were 1.59 million Health Care Workers (HCWs) and Frontline Workers (FLWs) of the Indian Armed Forces, who were administered COVISHIELD (Astra Zeneca). We present an interim analysis of vaccine effectiveness (VE) estimates till 30 May 2021.
The VIN-WIN cohort study was carried out on anonymized data of HCWs and FLWs of Indian Armed Forces. The existing surveillance system, enhanced for COVID-19 monitoring, was sourced for data. The cohort transitioned from Unvaccinated (UV) to Partially Vaccinated (PV) to Fully Vaccinated (FV), serving as its own internal comparison. Outcomes studied in the three groups were breakthrough infections and COVID related deaths. Incidence Rate Ratio (IRR) was used to compare outcomes among the three groups to estimate VE.
Data of 1,595,630 individuals (mean age 27.6 years; 99% male) over 135 days was analysed. Till 30 May 21, 95.4% and 82.2% were partially and fully vaccinated. The UV, PV and FV compartments comprised 106.6, 46.7 and 58.7 million person-days respectively. The number of breakthrough cases in the UV, PV and FV groups were 10061, 1159 and 2512; while the deaths were 37, 16 and 7 respectively. Corrected VE was 91.8-94.9% against infections.
Interim results of the VIN-WIN cohort study of 1.59 million HCWs and FLWs of Indian Armed Forces showed a ∼93% reduction in COVID-19 breakthrough infections with COVISHIELD vaccination.
2021年1月16日,印度启动了针对新冠病毒病的免疫计划。首批接种者包括159万名印度武装部队医护人员(HCW)和一线工作者(FLW),他们接种了牛津/阿斯利康新冠疫苗(COVISHIELD)。我们对截至2021年5月30日的疫苗效力(VE)估计值进行了中期分析。
VIN-WIN队列研究基于印度武装部队医护人员和一线工作者的匿名数据开展。利用为新冠病毒病监测强化的现有监测系统获取数据。该队列从未接种(UV)过渡到部分接种(PV)再到完全接种(FV),作为自身的内部对照。在三组中研究的结局为突破性感染和新冠病毒病相关死亡。发病率比(IRR)用于比较三组间的结局以估计疫苗效力。
分析了135天内1595630人的数据(平均年龄27.6岁;99%为男性)。截至2021年5月30日,95.4%和82.2%的人分别为部分接种和完全接种。未接种组、部分接种组和完全接种组的人天数分别为1.066亿、4670万和5870万。未接种组、部分接种组和完全接种组的突破性病例数分别为10061、1159和2512例;死亡数分别为37、16和7例。针对感染的校正疫苗效力为91.8% - 94.9%。
对159万名印度武装部队医护人员和一线工作者开展的VIN-WIN队列研究的中期结果显示,接种牛津/阿斯利康新冠疫苗后,新冠病毒病突破性感染减少了约93%。